GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (NAS:UTHR) » Definitions » FCF Yield %

United Therapeutics (United Therapeutics) FCF Yield % : 6.79 (As of Apr. 28, 2024)


View and export this data going back to 1999. Start your Free Trial

What is United Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, United Therapeutics's Trailing 12-Month Free Cash Flow is $748 Mil, and Market Cap is $11,005 Mil. Therefore, United Therapeutics's FCF Yield % for today is 6.79%.

The historical rank and industry rank for United Therapeutics's FCF Yield % or its related term are showing as below:

UTHR' s FCF Yield % Range Over the Past 10 Years
Min: -9.6   Med: 6.61   Max: 14.53
Current: 6.79


During the past 13 years, the highest FCF Yield % of United Therapeutics was 14.53%. The lowest was -9.60%. And the median was 6.61%.

UTHR's FCF Yield % is ranked better than
96.65% of 1550 companies
in the Biotechnology industry
Industry Median: -15.535 vs UTHR: 6.79

United Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 11.71%.


United Therapeutics FCF Yield % Historical Data

The historical data trend for United Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics FCF Yield % Chart

United Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.51 10.31 4.90 5.18 7.23

United Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.77 12.76 2.38 10.57 2.78

Competitive Comparison of United Therapeutics's FCF Yield %

For the Biotechnology subindustry, United Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, United Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where United Therapeutics's FCF Yield % falls into.



United Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

United Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=747.6 / 10343.735545
=7.23%

United Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=72 * 4 / 10343.735545
=2.78%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


United Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


United Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of United Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


United Therapeutics (United Therapeutics) Business Description

Traded in Other Exchanges
Address
1040 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Executives
Paul A Mahon officer: EVP & General Counsel
Nilda Mesa director C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Causey director
Martine A Rothblatt director, officer: Chief Executive Officer
Louis W Sullivan director
Judy D. Olian director 2000 AVENUE OF THE STARS 12TH FL, LOS ANGELES CA 90067
Michael Benkowitz officer: President and COO C/O UNITED THERAPEUTICS CORP, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Patusky director
Raymond Dwek director
Linda Maxwell director 1040 SPRING STREET, SILVER SPRING NC 27709
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Katherine J Klein director STEINBERG HALL-DIETRICH HALL, 3620 LOCUST WALK, PHILADELPHIA PA 19104
Richard Giltner director C/O UNITED THERAPEUTICS CORPORTION, 1735 CONNECTICUT AVE. NW, WASHINGTON DC 20009
Roger Jeffs director, officer: President and COO
David Zaccardelli officer: EVP & Chief Operating Officer 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069